Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: A critical review

Vaccine

Volumn 32, Issue 15, 2014, Pages 1645-1653

  Kawai, Kosuke ^a   Preaud, Emmanuelle ^b   Baron Papillon, Florence ^b   Largeron, Nathalie ^b   Acosta, Camilo J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

Cost effectiveness; Herpes zoster; Postherpetic neuralgia; Shingles; Vaccination; Vaccine

Indexed keywords

VARICELLA ZOSTER VACCINE;

COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EUROPE; HERPES ZOSTER; HUMAN; LIFESPAN; NORTH AMERICA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; REVIEW; SENSITIVITY ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT DURATION; VACCINATION;

COST-EFFECTIVENESS; HERPES ZOSTER; POSTHERPETIC NEURALGIA; SHINGLES; VACCINATION; VACCINE;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; EUROPE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MIDDLE AGED; NEURALGIA, POSTHERPETIC; NORTH AMERICA; QUALITY-ADJUSTED LIFE YEARS; VACCINATION;

EID: 84895873481     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.058     Document Type: Review

References (43)

1. Cohen J.I. Clinical practice: Herpes zoster. N Engl J Med. 2013 Jul 18, 369(3):255-263.
2. Hope-Simpson R.E. The Nature of Herpes Zoster: a Long-Term Study and a New Hypothesis. Proc R Soc Med. 1965 Jan, 58:9-20.
3. Yawn B.P., Saddier P., Wollan P.C., St Sauver J.L., Kurland M.J., Sy L.S. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007 Nov, 82(11):9-1341.
4. Pinchinat S., Cebrian-Cuenca A.M., Bricout H., Johnson R.W. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013, 13:170.
5. Johnson R.W., Bouhassira D., Kassianos G., Leplege A., Schmader K.E., Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010, 8:37.
6. Dworkin R.H., Johnson R.W., Breuer J., Gnann J.W., Levin M.J., Backonja M., et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 1, 44(Suppl 1):S1-S26.
7. Hope-Simpson R.E. Postherpetic neuralgia. J R Coll Gen Pract. 1975 Aug, 25(157):571-575.
8. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2, 352(22):2271-2284.
9. Schmader K.E., Oxman M.N., Levin M.J., Johnson G., Zhang J.H., Betts R., et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012 Nov 15, 55(10):1320-1328.
10. ZOSTAVAX Product Information. European Medicines Agency 27/03/2013 [cited; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000674/WC500053462.pdf.
11. Schmader K.E., Levin M.J., Gnann J.W., McNeil S.A., Vesikari T., Betts R.F., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012 Apr, 54(7):922-928.
12. Husereau D., Drummond M., Petrou S., Carswell C., Moher D., Greenberg D., et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health 2013 Mar Apr, 16(2). e1-5.
13. Organisation for Economic Co-operation and Development (OECD). Price indices (MEI). [cited 2013 November 27]; Available from: =MEI_PRICES. http://stats.oecd.org/Index.aspx%3FDataSetCode.
14. Szucs T.D., Pfeil A.M. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics. 2013 Feb, 31(2):125-136.
15. van Hoek A.J., Melegaro A., Gay N., Bilcke J., Edmunds W.J. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012 Feb 1, 30(6):1225-1234.
16. Bilcke J., van Hoek A.J., Beutels P. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?. Hum Vaccin Immunother. 2013 Apr, 9(4):812-822.
17. Wasem J., Lang K., Papageorgiou M., Ultsch B., Martin M. Health economic evaluation of a new vaccine for the prevention of herpes zoster and post-herpetic neuralgia in adults a German analysis. Value in Health. 2009, 12(7):A294.
18. Hornberger J., Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006 Sep 5, 145(5):317-325.
19. Rothberg M.B., Virapongse A., Smith K.J. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007 May 15, 44(10):1280-1288.
20. Pellissier J.M., Brisson M., Levin M.J. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007 Nov 28, 25(49):8326-8337.
21. Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008 May-Jun;4(3):238-45.
22. Najafzadeh M., Marra C.A., Galanis E., Patrick D.M. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009, 27(12):991-1004.
23. Edmunds W.J., Brisson M., Rose J.D. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001 Apr 30, 19(23-24):3076-3090.
24. van Hoek A.J., Gay N., Melegaro A., Opstelten W., Edmunds W.J. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009 Feb 25, 27(9):1454-1467.
25. Moore L., Remy V., Martin M., Beillat M., McGuire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc. 2010, 8:7.
26. Annemans L., Bresse X., Gobbo C., Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010, 13(3):537-551.
27. Bilcke J., Marais C., Ogunjimi B., Willem L., Hens N., Beutels P. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine. 2012 Jan 11, 30(3):675-684.
28. van Lier A., van Hoek A.J., Opstelten W., Boot H.J., de Melker H.E. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010, 10:237.
29. de Boer P.T., Pouwels K.B., Cox J.M., Hak E., Wilschut J.C., Postma M.J. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013 Feb 18, 31(9):1276-1283.
30. Szucs T.D., Kressig R.W., Papageorgiou M., Kempf W., Michel J.P., Fendl A., et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2012 Jul, 7(7):749-756.
31. Bresse X., Annemans L., Preaud E., Bloch K., Duru G., Gauthier A. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2013 Mar 28.
32. Ultsch B., Weidemann F., Reinhold T., Siedler A., Krause G., Wichmann O. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013, 13:359.
33. Coplan P.M., Schmader K., Nikas A., Chan I.S., Choo P., Levin M.J., et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004 Aug, 5(6):344-356.
34. Oster G., Harding G., Dukes E., Edelsberg J., Cleary P.D. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005 Jun, 6(6):356-363.
35. Helgason S., Petursson G., Gudmundsson S., Sigurdsson J.A. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ. 2000 Sep 30, 321(7264):794-796.
36. Bilcke J., Ogunjimi B., Hulstaert F., Van Damme P., Hens N., Beutels P. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?. Vaccine. 2012 Apr 5, 30(17):2795-2800.
37. Brisson M., Pellissier J.M., Levin M.J. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis. 2007 Dec 1, 45(11):1527-1529.
38. Levin M.J. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012 Aug, 24(4):494-500.
39. Watson C.P., Watt V.R., Chipman M., Birkett N., Evans R.J. The prognosis with postherpetic neuralgia. Pain. 1991 Aug, 46(2):195-199.
40. Bouhassira D., Chassany O., Gaillat J., Hanslik T., Launay O., Mann C., et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain. 2012 Feb, 153(2):342-349.
41. Johnson R.W., Wasner G., Saddier P., Baron R. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother. 2007 Nov, 7(11):1581-1595.
42. Beutels P., Scuffham P.A., MacIntyre C.R. Funding of drugs: do vaccines warrant a different approach?. Lancet Infect Dis. 2008 Nov, 8(11):727-733.
43. Bell C.M., Urbach D.R., Ray J.G., Bayoumi A., Rosen A.B., Greenberg D., et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006 Mar 25, 332(7543):699-703.